Receptor activated bladder and spinal ATP release in neurally intact and chronic spinal cord injured rats.
Neurally intact (NI) rats and chronic spinal cord injured (SCI) rats were studied to determine how activation of mechanosensory or cholinergic receptors in the bladder urothelium evokes ATP release from afferent terminals in the bladder as well as in the spinal cord. Spinal cord transection was performed at the T(9)-T(10) level 2-3 weeks prior to the experiment and a microdialysis fiber was inserted in the L(6)-S(1) lumbosacral spinal cord one day before the experiments. Mechanically evoked (i.e. 10 cm/W bladder pressure) ATP release into the bladder lumen was approximately 6.5-fold higher in SCI compared to NI rats (p<0.05). Intravesical carbachol (CCh) induced a significantly greater release of ATP in the bladder from SCI as compared to NI rats (3424.32+/-1255.57 pmol/ml versus 613.74+/-470.44 pmol/ml, respectively, p<0.05). However, ATP release in NI or SCI rats to intravesical CCh was not affected by the muscarinic antagonist atropine (Atr). Spinal release of ATP to bladder stimulation with 10 cm/W pressure was five-fold higher in SCI compared to NI rats (p<0.05). CCh also induced a significantly greater release of spinal ATP in SCI rats compared to controls (4.3+/-0.9 pmol versus 0.90+/-0.15 pmol, p<0.05). Surprisingly, the percent inhibitory effect of Atr on CCh-induced ATP release was less pronounced in SCI as compared to NI rats (49% versus 89%, respectively). SCI induces a dramatic increase in intravesical pressure and cholinergic receptor evoked bladder and spinal ATP release. Muscarinic receptors do not mediate intravesical CCh-induced ATP release into the bladder lumen in NI or SCI rats. In NI rats sensory muscarinic receptors are the predominant mechanism by which CCh induces ATP release from primary afferents within the lumbosacral spinal cord. Following SCI, however, nicotinic or purinergic receptor mechanisms become active, as evidenced by the fact that Atr was only partially effective in inhibiting CCh-induced spinal ATP release.
Salas
Nilson A
NA
NeuroUrology Laboratory, Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.
Somogyi
George T
GT
Gangitano
David A
DA
Boone
Timothy B
TB
Smith
Christopher P
CP
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000502:physiology; D002217:Carbachol / Q000494:pharmacology; D002908:Chronic Disease; D005260:Female; D017551:Microdialysis; D018721:Muscarinic Agonists / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism*; D011312:Pressure; D051381:Rats; D017207:Rats, Sprague-Dawley; D011950:Receptors, Cholinergic / Q000378:metabolism; D011983:Receptors, Purinergic / Q000187:drug effects; D013116:Spinal Cord / Q000166:cytology / Q000378:metabolism*; D013119:Spinal Cord Injuries / Q000378:metabolism*; D013268:Stimulation, Chemical; D001743:Urinary Bladder / Q000294:innervation / Q000378:metabolism*
D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D011950:Receptors, Cholinergic; D011983:Receptors, Purinergic; D001285:Atropine; D000255:Adenosine Triphosphate; D002217:Carbachol